Nilotinib hampers the proliferation and function of CD8(+) T lymphocytes through inhibition of T cell receptor signalling

The novel selective BCR-ABL Breakpoint cluster region – Abelson murine leukemia viral oncogene homolog 1 (BCR-AML) inhibitor nilotinib (AMN107) is a tyrosine kinase inhibitor that is more potent against leukaemia cells in vitro than imatinib. As nilotinib might be used in the context of allogeneic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, J, Schmitt, A, Chen, B, Rojewski, M, RuBeler, V, Fei, F, Yu, Y, Yu, X, Ringhoffer, M, von Harsdorf, S, Greiner, J, Gbtzz, M, Guillaume, P, Dbhner, H, Bunjes, D, Schmitt, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2008
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506175/
https://www.ncbi.nlm.nih.gov/pubmed/18194453
http://dx.doi.org/10.1111/j.1582-4934.2008.00234.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506175/
https://www.ncbi.nlm.nih.gov/pubmed/18194453
http://dx.doi.org/10.1111/j.1582-4934.2008.00234.x

Ejemplares similares